



# NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 15 Dec 2017 (#47)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit [www.grants.nih.gov](http://www.grants.nih.gov).

**Confirm your intent to apply ASAP, but not later than 30 days before the submission date.**

Contact: RGMO Pre-Awards [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za)

## Important Notices:

[View the slideshow](#)

- [Selected NIAID Science News Highlights of 2017](#)
- [NIH Issues Parent R01, R21 Clinical Trial Funding Opportunities](#) NIAID plans to discontinue the funding opportunity announcement (FOA) NIAID Clinical Trial Implementation Grant (R01) and in its place use two new NIH clinical trial FOAs for investigator-initiated research
- [Updated FOAs: Titles Tell You Yes, No, or Maybe About Clinical Trials](#) NIH is issuing (or reissuing) funding opportunity announcements with titles that specify whether clinical trials are optional, required, or not allowed.
- [NIAID Sets Interim Paylines for Beginning of FY 2018](#) NIAID sets interim paylines early in the fiscal year at a conservative level. Later in the fiscal year, once we better understand how many applications we've received and how much money is available, we adjust the paylines to their final amounts.
- [Learn About NIAID's Genomic Data Sharing Policy](#) Visit the NIAID Genomic Data Sharing policy page for in-depth coverage of when the policy applies, data submission and release, sample data sharing plans and templates, informed consent for sharing data from human samples, institutional certification, exceptions, and contact information
- Focus on how [Americans benefit from global health research](#)
- [NIH Single IRB Policy Reminder](#) As we approach the implementation date for NIH's Policy on the Use of a Single Institutional Review Board (Single IRB) for Multi-Site Research, we would like to remind you of the resources available for understanding this policy
- The new [Preparing Your Application Using ASSIST](#) page provides step-by-step guidance for navigating the submission process using ASSIST, NIH's online submission system for the preparation, submission and tracking of grant applications to NIH.
- [mHealth Training Institute](#) July 29 - August 3, 2018. Conducted and hosted by the University of California, Los Angeles, and sponsored in part by NIH. Foreign applicants are welcome. There are no registration fees for participants, who also receive accommodations and meals. Application deadline: January 27, 2018
- [Findings of Research Misconduct \(NOT-OD-18-113\)](#)

### 1. Understanding Immunopathogenesis of Tuberculosis in HIV-1 Infected and Exposed Children (Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(RFA-AI-17-039\)](#)

**Type:** R01

**Application Due Date:** March 14, 2018. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The purpose of this Funding Opportunity Announcement (FOA) is to support research that will identify changes in immune mechanisms and markers because of Mycobacterium tuberculosis (M.tb) exposure, infection or disease in pediatric populations exposed to or infected with HIV-1.

**Budget:** NIAID intends to commit \$3.8 million in FY 2019 to fund 3 to 5 awards. Application budgets for studies proposing to use non-human primates are capped at \$850,000 (direct costs) per year. Application budgets for all other applications are capped at \$500,000 (direct costs) per year. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

## 2. Revisions for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (Clinical Trials Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(RFA-CA-18-006\)](#)

**Type:** R01

**Application Due Date:** February 28, 2018; May 29, 2018; September 28, 2018. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI R01 research projects proposing to expand upon the original research question(s) or otherwise accelerate progress for the parent study by incorporating a new technical approach or instrument developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program. Awards from this FOA are meant to incentivize independent validation and accelerate the adoption of these emerging technologies by appropriate research communities. As a component of the NCI IMAT program, this FOA aims to promote interdisciplinary collaboration in the development of innovative tools and methods that enable cancer research and accelerate scientific discovery.

**Budget:** NCI intends to fund an estimate of 3 awards, corresponding to a total of \$600,000, for fiscal year 2019. Future year amounts will depend on annual appropriations. Application budgets may not exceed \$150,000 in direct costs per year. Applicants may request support for up to 2 years, not to exceed the remaining number of years on the parent grant. If a no-cost extension is needed on the parent grant, it must be in place before the revision application is submitted

## 3. National Institute on Drug Abuse (NIDA) Avant-Garde Award Program for HIV/AIDS and Drug Use Research (Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(RFA-DA-18-019\)](#)

**Type:** DP1

**Application Due Date:** August 14, 2018; August 14, 2019; August 14, 2020. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The NIDA Avant-Garde Award Program for HIV/AIDS Research supports individual scientists of exceptional creativity who propose high-impact research that will open new areas of HIV/AIDS research relevant to drug abuse and/or lead to new avenues for prevention and treatment of HIV/AIDS among drug abusers. The term "avant-garde" is used to describe highly innovative approaches that have the potential to be transformative. The proposed research should reflect approaches and ideas that are substantially different from those already being pursued by the investigator or others and should support the NIH HIV/AIDS Research Priorities <https://grants.nih.gov/grants/guide/notice-files/NOT-OD-15-137.html>. The NIDA Avant-Garde award supports innovative, basic research that may lead to improved preventive interventions or therapies; creative, new strategies to prevent disease transmission; novel approaches to improve disease outcomes; and creative approaches to eradicating HIV or improving the lives of those living with HIV.

**Budget:** NIDA intends to commit \$2M in each fiscal year to fund 2-3 awards each year. Application budgets are limited to \$500,000 in direct costs per year. The maximum period is 5 years.

## 4. National Institute on Drug Abuse (NIDA) Translational Avant-Garde Award for Development of Medication to Treat Substance Use Disorders (Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(RFA-DA-18-020\)](#)

**Type:** UG3/UH3

**Application Due Date:** July 25, 2018; July 25, 2019, July 25, 2020. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The purpose of this award is to support outstanding basic and/or clinical researchers with the vision and expertise to translate research discoveries into medications for the treatment of Substance Use Disorders (SUDs) stemming from tobacco, cannabis, cocaine, methamphetamine, heroin, or prescription opiate use. Eligible applicants must demonstrate the ability to develop molecules with the potential to treat SUDs and advance them in the drug development continuum. The ultimate goal of this FOA is to bring molecules closer to FDA approval. The UG3/UH3 Phased Innovation Awards Cooperative Agreement involves 2 phases. The UG3 will support a project with specific milestones to be accomplished at the end of the 2-year period. The UH3 will provide funding for 3 years to a project that successfully completed the milestones set in the UG3. UG3 projects that have met their milestones will be administratively considered by NIDA and prioritized for transition to the UH3 phase. Investigators responding to this FOA must address both UG3 and UH3 phases. Through this FOA, NIDA seeks to attract exceptionally talented investigators to the mission of expanding the number and breadth of lead molecules in the pipeline for drug addiction treatment, optimizing these leads, and/or advancing them to clinical testing.

**Budget:** NIDA intends to commit \$2,000,000 in FY17, FY18 and FY19 to fund up to 2 awards each year. Application budgets are limited to \$1,000,000 direct costs per year and need to reflect the actual needs of the proposed project. The project period is limited to 2 years for the UG3 phase and 3 years for the UH3 phase.

## 5. Planning Grant to Develop Phase III Clinical Trials for Lewy Body Dementia (clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(RFA-NS-18-017\)](#)

**Type:** R34

**Application Due Date:** March 20, 2018. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The purpose of this FOA is to provide one year of support for planning activities necessary for initiating a Phase III clinical trial designed to treat patients with Lewy Body Dementias (LBD), which include Dementia with Lewy Bodies and Parkinson's Disease Dementia. Such activities may include identifying trial sites/collaborators, designing trial protocols and procedures, and addressing regulatory approvals.

**Budget:** NIA intends to commit up to \$750,000 in FY 2018 to fund up to five awards. Application budgets are limited to \$150,000 in direct costs over one year. The amount requested must reflect the actual needs of the proposed project. The project period is limited to one year.

**6. National Eye Institute (NEI) Audacious Goals Initiative: Translation-Enabling Models to Evaluate Survival and Integration of Regenerated Neurons in the Visual System (Clinical Trials Not Allowed)**

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(RFA-EY-17-003\)](#)

**Type:** U24

**Application Due Date:** February 21, 2018. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The purpose of this FOA is to stimulate development of translation-enabling models for evaluating survival and integration of regenerated photoreceptors (PRCs) and retinal ganglion cells (RGCs) in model systems that are closer to human visual anatomy, function and/or disease than current models. The development of these models, tools, devices, novel therapies and/or other resources is expected to provide a resource to vision researchers developing cell-replacement therapies for visual system diseases and disorders. This FOA seeks to develop models that emulate critical aspects of a human blinding disease that might be amenable to regenerative therapy. The model system might involve specific defects generated by transgenic gene insertion and/or deletion, gene editing, chemical/physical means, and/or other approaches to emulate characteristics of human disease or create defects amenable to cell-replacement therapy. Model systems using non-human primates or other cone-dominant species that are more representative of the anatomy and physiology of the human retina are highly encouraged. Other biological models are acceptable provided they meet the overall objectives of the FOA. An important aspect of this FOA is that the research team is expected to treat the loss of vision associated with the experimental model using an approach that involves regenerating PRCs and/or RGCs and their connections. The choice of cells for therapy might include adult stem cells, precursors, stem cell derived progenitor cells, or conversion of intrinsic cells such as glia. It is expected that quantitative measures will be used to evaluate survival and integration of the regenerated cells using electrophysiology, functional imaging, behavioral measures or any other appropriate technology that would demonstrate circuit integration and restoration of visual function.

**Budget:** The NEI intends to commit \$5-6 million in FY 2018 to fund 3-4 awards. Applicants may request up to \$1 million per year direct costs (exclusive of consortium facilities and administrative costs). The scope of the proposed project should determine the project period. The maximum project period is 5 years.

**7. Obesity and Asthma: Awareness and Self- Management (Clinical Trial Optional)**

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(PA-18-379\)](#)

**Type:** R01

**Application Due Date:** [Standard dates](#) and [Standard AIDS dates](#) Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The purpose of this Funding Opportunity Announcement (FOA) is to encourage research that examines the relationship between asthma, obesity and self-management. It seeks to build the science of obesity, asthma, and self-management awareness.

**Budget:** Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

**8. Developing the Therapeutic Potential of the Endocannabinoid System for Pain Treatment (Clinical Trial Optional)**

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(PA-18-465\)](#)

**Type:** R01

**Application Due Date:** [Standard dates](#) and [Standard AIDS dates](#) Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The purpose of this Funding Opportunity Announcement (FOA) is to support projects that will elucidate the therapeutic potential of the cannabinoids and endocannabinoid system in the development of mechanism-based therapies for pain.

**Budget:** Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

**9. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Research Project Grant (Clinical Trial Required)**

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(PA-18-480\)](#)

**Type:** R01

**Application Due Date:** [Standard dates](#) and [Standard AIDS dates](#) Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The NICHD Research Project Grant (Clinical Trial Required) supports clinical trials that fall within the NICHD mission

**Budget:** Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

**10. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Small Grant Program (Clinical Trial Optional)**

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(PA-18-481\)](#)

**Type:** R03

**Application Due Date:** [Standard dates](#) and [Standard AIDS dates](#) Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The NICHD Investigator-Initiated Small Research Grant (R03) funding opportunity supports small research projects that can be carried out in a short period of time with limited resources. The R03 activity code supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.

**Budget:** Application budgets are limited to \$50,000 in direct costs per year. The scope of the proposed project should determine the project period. The maximum project period is 2 years.

### 11. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Exploratory/Developmental Research Grant (Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(PA-18-482\)](#)

**Type:** R21

**Application Due Date:** [Standard dates](#) and [Standard AIDS dates](#) Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The NICHD Exploratory/Developmental Grant program supports exploratory and developmental research projects that fall within the NICHD mission by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research.

**Budget:** Direct costs are limited to \$275,000 over a two-year period, with no more than \$200,000 in direct costs allowed in any single year. The scope of the proposed project should determine the project period. The maximum project period is 2 years.

### 12. NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(PA-18-484\)](#)

**Type:** R01

**Application Due Date:** [Standard dates](#) and [Standard AIDS dates](#) Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The NIH Research Project Grant supports a discrete, specified, circumscribed project in areas representing the specific interests and competencies of the investigator(s). The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. This Funding Opportunity Announcement does not accept applications proposing clinical trial(s).

**Budget:** Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

### 13. NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(PA-18-488\)](#)

**Type:** R03

**Application Due Date:** [Standard dates](#) and [Standard AIDS dates](#) Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The NIH Small Research Grant Program supports small research projects that can be carried out in a short period of time with limited resources. This program supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. This Funding Opportunity Announcement does not accept applications proposing clinical trial(s).

**Budget:** Application budgets are limited to \$50,000 in direct costs per year. The total project period may not exceed two years.

### 14. NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(PA-18-489\)](#)

**Type:** R21

**Application Due Date:** [Standard dates](#) and [Standard AIDS dates](#) Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The NIH Exploratory/Developmental Grant supports exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research.

**Budget:** The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year. The total project period may not exceed 2 years.

### 15. Effectiveness Trials for Post-Acute Interventions and Services and Services to Optimize Longer-Term Outcomes (Clinical Trials Required)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(PAR-18-430\)](#)

**Type:** R01

**Application Due Date:** [Standard dates](#) and [Standard AIDS dates](#) Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** National Institute of Mental Health (NIMH) seeks applications for research projects to evaluate the effectiveness of therapeutic and service delivery interventions for the post-acute management of mental health conditions affecting youth, adults, and older adults. This FOA encourages clinical trials to establish the effectiveness and test hypotheses regarding moderators, mediators, and mechanisms of action of post-acute phase therapeutic and services interventions that are matched to the stage of illness in terms of both their focus (e.g., consolidating and maintaining gains from initial treatment, managing residual symptoms/impairment, preventing relapse, promoting adherence and appropriate service use) and intensity/burden for promoting optimal longer-term outcomes. This FOA is intended to support effectiveness trials testing post-acute phase interventions that are statistically powered to provide a definitive answer regarding the study intervention's effectiveness. Support for pilot effectiveness trials to evaluate the initial feasibility, tolerability, acceptability, safety and preliminary indications of effectiveness of post-acute phase intervention approaches is provided via the R34 in PAR-18-422.

**Budget:** Application budgets are not limited but need to reflect the actual needs of the proposed project. Scope of the proposed project should determine the project period. The maximum period is 5 years, however, most awards will be for 3-4 years.

## 16. National Institute of Neurological Disorders and Stroke Promoting Research in Basic Neuroscience

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(PAS-18-483\)](#)

**Type:** R01

**Application Due Date:** [Standard dates](#) and [Standard AIDS dates](#) Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The goal of this Funding Opportunity Announcement (FOA) is to stimulate research addressing fundamental questions in basic neuroscience. Proposed projects can address any area of neuroscience within the missions of the participating institutes and should focus on understanding the development, the structure and/or the function of the normal nervous system. While fundamental basic research often generates insights relevant to disorders of the nervous system, this FOA is not intended to stimulate research that is explicitly disease-related.

**Budget:** NINDS intends to fund up to 12 awards, corresponding to a total of \$5.0 million for fiscal year 2019. Future year amounts will depend on annual appropriations. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

## 17. Pilot Effectiveness Trials for Post-Acute Interventions and Services to Optimize Longer-Term Outcomes (Clinical Trials Required)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(PAR-18-431\)](#)

**Type:** R34

**Application Due Date:** [Standard dates](#) Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** National Institute of Mental Health (NIMH) seeks applications for pilot effectiveness projects to evaluate the preliminary effectiveness of therapeutic and service delivery interventions for the post-acute management of mental health conditions that are matched to the stage of illness in terms of both their focus (e.g., consolidating and maintaining gains from initial treatment, managing residual symptoms/impairment, preventing relapse, promoting adherence and appropriate service use) and intensity/burden. In this pilot phase of effectiveness research, the trial should be designed to evaluate the feasibility, tolerability, acceptability, safety, and potential effectiveness of the approach; to address whether the intervention engages the target(s)/mechanism(s) that is/are presumed to underlie the intervention effects; and to obtain preliminary data needed as a pre-requisite to a larger-scale effectiveness trial (e.g., comparative effectiveness study, practical trial) designed to definitely test the effectiveness of interventions to improve post-acute outcomes. This FOA supports pilot effectiveness research to evaluate the feasibility, tolerability, acceptability, safety and preliminary indications of effectiveness of post-acute phase intervention approaches and inform the design of definitive effectiveness trials. Support for fully-powered, definitive effectiveness studies focused on post-acute phase interventions is provided via the R01 in PAR-18-423.

**Budget:** Direct costs are limited to \$450,000 over the R34 project period, with no more than \$225,000 in direct costs allowed in any single year. The total project period may not exceed three years.

**Brief definitions of some NIH grant mechanisms:** [comprehensive list of extramural grant and cooperative agreement activity codes](#)

**R01 – NIH Research Project Grant Program:** most common NIH program; to support a discrete, specified, circumscribed research project; generally 3-5 years; budget may be specified, but generally <\$500,000 p.a. (direct costs).

**R21 – NIH Exploratory/Developmental Research Grant:** encourages new, exploratory and developmental research projects (could be used for pilot or feasibility studies); up to 2 years; budget total generally <\$275,000 (direct costs).

**R03 – NIH Small Grant Program:** limited funding for short period to support e.g. pilot / feasibility study, collection of preliminary data, secondary analysis of existing data, small-contained research projects, development of new research technology, etc.; normally for “new investigators”; not renewable; up to 2 years; budget generally <\$50,000 (direct costs).